Novo Nordisk has announced it has completed the second Phase IIIa trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilises Emisphere Technologies’ proprietary Eligen® Technology.
Emisphere is a drug delivery company that utilises its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere partners with global pharmaceutical companies for the development of new orally delivered therapeutics.